Diabetes drug pioglitazone (Actos): risk of fracture
| Autor: | Eric Wooltorton, Reza Heidarpour Meymeh |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Drug
Male medicine.medical_specialty Combination therapy media_common.quotation_subject Osteoporosis Fractures Bone Sex Factors Internal medicine Diabetes mellitus medicine Humans Hypoglycemic Agents media_common Randomized Controlled Trials as Topic Practice Pioglitazone business.industry Type 2 Diabetes Mellitus General Medicine medicine.disease Surgery Clinical trial Increased risk Diabetes Mellitus Type 2 Female Thiazolidinediones business medicine.drug |
| Zdroj: | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 177(7) |
| ISSN: | 1488-2329 |
| Popis: | Reason for posting: Pioglitazone is an oral hypoglycemic agent widely used as monotherapy or combination therapy for type 2 diabetes mellitus. However, a recent analysis by the drug's manufacturer of several unpublished clinical trials in the company's database revealed an increased risk of bone |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|